Bank of America Lowers Bristol Myers Squibb (NYSE:BMY) Price Target to $67.00

Bristol Myers Squibb (NYSE:BMY) had its price objective reduced by research analysts at Bank of America from $68.00 to $67.00 in a report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Bank of America‘s target price would indicate a potential upside of 12.98% from the stock’s current price.

A number of other equities analysts have also recently issued reports on BMY. Citigroup increased their target price on Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a report on Friday, February 6th. Wells Fargo & Company reaffirmed an “outperform” rating and set a $60.00 price target (up from $55.00) on shares of Bristol Myers Squibb in a report on Friday, February 6th. UBS Group reissued a “buy” rating and issued a $70.00 target price on shares of Bristol Myers Squibb in a research note on Friday, March 6th. HSBC lifted their target price on Bristol Myers Squibb from $53.00 to $60.00 and gave the company a “hold” rating in a research note on Tuesday, March 17th. Finally, Guggenheim reissued a “buy” rating and issued a $72.00 target price on shares of Bristol Myers Squibb in a research note on Wednesday. Nine research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Bristol Myers Squibb presently has an average rating of “Hold” and a consensus price target of $61.71.

Bristol Myers Squibb Price Performance

Shares of BMY traded up $0.10 during mid-day trading on Thursday, reaching $59.30. The company had a trading volume of 2,013,165 shares, compared to its average volume of 13,169,014. Bristol Myers Squibb has a twelve month low of $42.52 and a twelve month high of $62.89. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The company’s 50-day moving average is $59.60 and its 200-day moving average is $52.98. The company has a market capitalization of $121.08 billion, a P/E ratio of 17.19, a P/E/G ratio of 0.17 and a beta of 0.27.

Bristol Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The company had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same period in the previous year, the company posted $1.67 earnings per share. The company’s quarterly revenue was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts anticipate that Bristol Myers Squibb will post 6.74 EPS for the current year.

Insider Activity

In other news, EVP David V. Elkins sold 30,000 shares of the firm’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares in the company, valued at $9,820,824.16. This trade represents a 15.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.09% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in BMY. Norges Bank bought a new position in shares of Bristol Myers Squibb in the 4th quarter worth $1,947,272,000. AQR Capital Management LLC lifted its holdings in Bristol Myers Squibb by 172.6% during the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company’s stock worth $1,391,485,000 after acquiring an additional 16,332,924 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Bristol Myers Squibb by 47.0% during the fourth quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company’s stock worth $1,321,308,000 after acquiring an additional 7,837,485 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company’s stock worth $2,837,026,000 after acquiring an additional 6,084,046 shares in the last quarter. Finally, Man Group plc lifted its holdings in Bristol Myers Squibb by 280.4% during the second quarter. Man Group plc now owns 7,465,845 shares of the biopharmaceutical company’s stock worth $345,594,000 after acquiring an additional 5,503,391 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Announced a multi‑year collaboration with Oxford BioTherapeutics to discover and develop next‑generation T‑cell engagers for solid tumors — reinforces BMS’s oncology pipeline-building strategy and reduces execution risk on early discovery. Oxford BioTherapeutics Collaboration
• Positive Sentiment: Guggenheim reaffirmed a Buy on BMY with a $72 price target, supporting upside narrative from longer‑term pipeline and dividend yield. Guggenheim Buy
• Positive Sentiment: Piper Sandler initiated/maintained a Buy, adding to the broker support that likely helped lift sentiment in recent sessions. Piper Sandler Buy
• Neutral Sentiment: Cantor Fitzgerald raised its price target to $54 but kept a Neutral rating and cautioned that Q1 is not likely to be a dramatic catalyst — mixed signal for near‑term momentum. Cantor Fitzgerald Note
• Neutral Sentiment: BofA reports that biopharma names are largely exempt from proposed pharma tariffs — sector tailwind but not a company‑specific catalyst. BofA Tariff Note
• Neutral Sentiment: Recent intraday/previous-session price action showed a ~2.6% gain, reflecting the positive reaction to the collaboration and analyst activity. Price Action
• Negative Sentiment: Earnings risk: previews and analyst commentary expect a double‑digit percentage decline in Q1 EPS, and BMY missed EPS in its last reported quarter — near‑term results and guidance remain key downside risks. Earnings Preview

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.